Jason Holder, MD
Pulmonary Disease · Little Rock, ARNPI 1790909950
Payments from drug & device makers
Across 91 payments — averaging $23.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$484
- Boehringer Ingelheim$222
- Stryker$184
- Grifols USA, LLC$151
- AstraZeneca$143
- Electromed, Inc.$139
- plus $834 from 15 others
What the payments were for
- Food & beverage$2,13899%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 33 | $484 |
| Boehringer Ingelheim | 9 | $222 |
| Stryker | 1 | $184 |
| Grifols USA, LLC | 6 | $151 |
| AstraZeneca | 9 | $143 |
| Electromed, Inc. | 5 | $139 |
| Intuitive Surgical | 1 | $134 |
| Mylan Specialty L.p. | 6 | $132 |
| Mallinckrodt Hospital Products Inc. | 4 | $120 |
| Baxter Healthcare | 2 | $80 |
| Sanofi | 2 | $69 |
| United Therapeutics Corporation | 2 | $51 |
| La Jolla Pharmaceutical Company | 2 | $45 |
| Philips North America LLC | 2 | $40 |
| Shionogi Inc | 1 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Inari Medical, Inc. | 1 | $31 |
| Merck | 1 | $20 |
| Amgen | 1 | $18 |
| Inogen, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,156 in reported general payments places this provider in the 35th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 22 | $284,157 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 258 | $225,564 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 67 | $45,695 |
| Breo ElliptaFluticasone/Vilanterol | 76 | $32,611 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 59 | $28,600 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $8,814 |
| Arnuity ElliptaFluticasone Furoate | 27 | $5,467 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 174 | $5,325 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,098 |
| Ventolin HfaAlbuterol Sulfate | 43 | $2,812 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $2,567 |
| Roflumilast | 14 | $2,288 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $1,927 |
| Montelukast Sodium | 113 | $978 |
| Fluticasone Propionate | 58 | $653 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $222 | $292,97141 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $484 | $292,242420 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $143 | $48,79378 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Little Rock
- Larry JohnsonLittle Rock$847K
- Nikhil MeenaLittle Rock$574K
- Raghu ReddyLittle Rock$541K
- Rajani JaganaLittle Rock$61K
- Hanan Khadam-MakhoulLittle Rock$15K
- Krishna Siva Sai KakkeraLittle Rock$14K
- Eyad AbochaleLittle Rock$11K
- Samer HomsiLittle Rock$9K
- Nathan HillLittle Rock$9K
- Jose CaceresLittle Rock$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.